Pasteur Biosciences

Pasteur Biosciences is an early cancer detection company with a strong focus on EVs, continuous improvements, and major innovations.

Extracellular Vesicle Focus

EVs are abundant and the most conserved biomolecule holders in all human biofluids. EVs have 1000+ times the amount of cancer biomarkers than cell-free DNA and cell-free RNA combined per unit of biofluid.

Proven Track Record

Helped to develop the best ovarian cancer test in the world and co-created the fastest and most sensitive anaphylaxis test in the world.

Transparency

We pride ourselves on transparency. Ask us anything about the science and our backgrounds.

Colocalization

Colocaliation of cancer biomarkers from the same EV drastically improves the statistical power and specificity of cancer type detected.

Continuous Improvements

Constant improvements are the nutrients and oxygen for an unrivaled company.

Love of Progress

Progress correlates with the number of lives saved, so we love making progress

Lung cancer is the leading cause of cancer-related deaths in the United States
Current diagnostic methods are not applicable to the general population and have exceedlingly high false positive rates. Additionally, the gold standard of ct scanning for lung cancer leads to an increased risk of overall cancer due to the x ray exposusure from ct scans.

The EV revolution is at hand. Join us in our endeavor to develop a general use and biofluid-based early-stage lung cancer test.

Get Started now

The Team

We endeavor to create a test with 99% sensitivity and 99% specificity for stage 1 lung cancer.
Christopher Sedlak
Chief Executive Officer and Lead Engineer
Michael
Chief Scientific Officer

Contact us now!

170 Brookline Ave, Boston MA
+1 586 707-3798
crsedlak@umich.edu
HomeAbout usContact

© 2024 Pasteur Biosciences‍